The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.

Female; Fluorodeoxyglucose F18/diagnostic use; Humans; Male; Neoplasm Staging/methods; Neoplasms/pathology/radionuclide imaging/therapy; Radiopharmaceuticals/diagnostic use; Sensitivity and Specificity; Tomography, Emission-Computed/methods

Disciplines :

Hematology

Author, co-author :

Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.

Publication date :

2002

Journal title :

Annals of Oncology

ISSN :

0923-7534

eISSN :

1569-8041

Publisher :

Oxford University Press, London, United Kingdom

Volume :

13 Suppl 4

Pages :

227-34

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 March 2009

Statistics

Number of views

49 (5 by ULiège)

Number of downloads

13 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In Warburg O (ed.): Metabolism of Tumors. London: Constable 1930; 254-270.
Gallagher BM, Fowler JS, Gutterson NI et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154-1161.
Gould MK, Maclean CC, Kuschner WG et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914-924.
Coleman RE, Laymon CM, Turkington TG. FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. Radiology 1999; 210: 823-828.
Higashi K, Ueda Y, Seki H et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39: 1016-1020.
Rege SD, Hoh CK, Glaspy JA et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
Coleman RE. PET in lung cancer. J Nucl Med 1999; 40: 814-820.
Gambhir SS, Shepherd JE, Shah BD et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998; 16: 2113-2125.
Laking G, Price P. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer. Thorax 2001; 56 (Suppl. 2): ii38-ii44.
Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999; 213: 530-536.
Gambhir SS, Hoh CK, Phelps ME et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998; 66: 1876-1883.
Kosuda S, Ichihara K, Watanabe M et al. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(l8)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest 2000; 117: 346-353.
Dietlein M, Weber K, Gandjour A et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27: 1598-1609.
van Tinteren H, Hoekstra OS, Smit EF et al. Randomized controlled trial (RCT) to evaluate the cost-effectiveness of positron emission tomography (PET) added to conventional diagnosis in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19: 482a (Abstr 1885).
Boyer MJ, Viney R, Fulham M et al. A randomized trial of conventional staging (CS) in patients (pts) with stage 1 or 2 non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 309a (Abstr 1233).
Schechter NR, Gillenwater AM, Byers RM et al. Can positron emission tomography improve the quality of care for head-and-neck cancer patients? Int J Radiat Oncol Biol Phys 2001; 51: 4-9.
Lonneux M, Lawson G, Ide C et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110: 1493-1497.
Huebner RH, Park KC, Shepherd JE et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189.
Strasberg SM, Dehdashti F, Siegel BA et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001; 233: 293-299.
Brennan MF. PET scanning in malignancy: infant, adolescent or mature citizen? Ann Surg 2001; 233: 320-321.
Flanagan FL, Dehdashti F, Ogunbiyi OA et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227: 319-323.
Sendler A, Avril N, Helmberger H et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000; 24: 1121-1129.
Kasperk RK, Riesener KP, Wilms K, Schumpelick V. Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view. World J Surg 2001; 25: 1134-1139.
Flamen P, Lerut A, Van Cutsem E et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-3210.
Block MI, Patterson GA, Sundaresan RS et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64: 770-776.
Wagner JD, Schauwecker D, Davidson D et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17: 1508-1515.
Acland KM, Healy C, Calonje E et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19: 2674-2678.
Tyler DS, Onaitis M, Kherani A et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89: 1019-1025.
Mijnhout GS, Hoekstra OS, van Tulder MW et al. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001; 91: 1530-1542.
Bangerter M, Moog F, Buchmann I et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-1122.
Wiedmann E, Baican B, Hertel A et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999; 34: 545-551.
Partridge S, Timothy AR, O'Doherty MJ. 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273.
Hueltenschmidt B, Sautter-Bihl ML, Lang O et al. Whole body positron emission tomography in the treatment of Hodgkin's disease. Cancer 2001; 91: 302-310.
Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
Buchmann I, Reinhardt M, Elsner K et al. 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91: 889-899.
Jerusalem G, Beguin Y. Commentary on "Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography". Clin Lymphoma 2000; 1: 75-76.
Romer W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
Jerusalem G, Beguin Y, Fassotte MF et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613-618.
de Wit M, Bohuslavizki KH, Buchert R et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood 2001; 98: 2930-2934.
Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.
Zinzani PL, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1181-1184.
Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27: 1564-1578.
Schluter B, Bohuslavizki KH, Beyer W et al. Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42: 71-76.
Avril N, Dose J, Janicke F et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88: 1204-1209.
Jansson T, Westlin JE, Ahlstrom H et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13: 1470-1477.
Schelling M, Avril N, Nahrig J et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-1695.
Smith IC, Welch AE, Hutcheon AW et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676-1688.
Kole AC, Nieweg OE, Pruim J et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82: 1160-1166.
Lassen U, Daugaard G, Eigtved A et al. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999; 35: 1076-1082.
Bohuslavizki KH, Klutmann S, Kroger S et al. FDG-PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816-822.
Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26: 308-314.
Weinblatt ME, Zanzi I, Belakhlef A et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997; 38: 888-890.
Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) in the follow-up of patients with Hodgkin's disease (HD). Proc Am Soc Clin Oncol 2000; 19: 10a (Abstr 30).
Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[fluorine-18]-fluoro-D-glucose. Radiology 1996; 199: 751-756.
Jerusalem G, Beguin Y, Fassotte MF et al. Evaluation thérapeutique précoce par tomographie à émission de positons. Med Hyg 2000; 58: 1629-1632.
Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
Valk PE, Pounds TR, Tesar RD et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996; 23: 737-743.